市场调查报告书
商品编码
1467994
数位病理检测市场:按产品类型、应用和最终用户划分 - 2024-2030 年全球预测Digital Pathology Market by Product (Scanners, Software, Storage Systems), Type (Human Pathology, Veterinary Pathology), Application, End-User - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
预计2023年数位病理检测市场规模为18.5亿美元,预计2024年将达21.1亿美元,2030年将达到48.1亿美元,复合年增长率为14.58%。
数位病理学是指在数位环境中捕获、管理、共用和解释病理讯息,包括幻灯片和资料。数位病理检测旨在提高病理评估的效率和准确性,促进医学领域诊断、研究和教育方面更好的决策。它利用先进的影像处理技术、电脑演算法和资料分析技术,更准确、更全面地检查组织样本,使病理学家能够更清晰、更详细地检测疾病和状况。由于慢性病盛行率不断上升,对高品质诊断的需求不断增长,并促进远距医疗提供快速、准确的分析并改善患者预后,数位病理测试市场正在快速增长。然而,市场受到显着障碍的困扰,包括系统整合挑战,以及与实施数位系统相关的高成本和资料安全问题。儘管存在这些障碍,人工智慧(AI)和用于分析自动化的机器学习、随着医疗基础设施的发展而扩展到新兴市场以及增加全球研究合作的潜力仍然存在快速增长的机会,显示出巨大的增长前景。这种市场格局代表了一个正在经历重大演变的市场,预计将重新定义病理诊断和医疗保健服务。
主要市场统计 | |
---|---|
基准年[2023] | 18.5亿美元 |
预测年份 [2024] | 21.1亿美元 |
预测年份 [2030] | 48.1亿美元 |
复合年增长率(%) | 14.58% |
越来越多地转向云端基础的解决方案,以获得比产品更灵活、更具成本效益的储存选项
数位病理扫描仪是一种先进的设备,用于透过捕捉高解析度影像将传统玻璃载玻片转换为数位载玻片。实验室可以根据吞吐量需求、解析度要求以及通常处理的检体类型来选择扫描器。高通量扫描器是标准实验室和学术中心等大批量检体环境中的首选,而较小的诊所可能会选择紧凑、低通量的型号。数位病理学测试中包含的软体包括影像分析工具、工作流程管理系统和远端病理学解决方案。这些解决方案可实现详细分析、远端存取和高效的案例管理,从而增加数位投影片的价值。数位病理测试会产生大量资料,需要强大的储存解决方案。根据业务规模、资料安全要求和可存取性需求选择储存解决方案。较大的机构可能需要高度扩充性的云端基础的解决方案,而较小的实验室可能会选择初始成本较低的小型资料库系统。
应用 更多采用数位病理学测试,以提高识别潜在治疗标靶和了解疾病机制的速度和准确性
数位病理学测试在疾病诊断中的应用使病理学家透过数位化玻片并使用数位影像进行分析,能够更准确、更有效率地诊断包括癌症在内的疾病。这种模式支持各种诊断程序,包括分析癌细胞、对肿瘤样本进行分级和监测疾病进展。数位病理测试在药物发现过程中发挥重要作用,特别是在药物疗效评估和毒性测试中。透过对组织样本进行数字分析,研究人员可以在微观层面上更好地了解候选药物的作用。数位病理学测试透过提供大量数位幻灯片进行教学和协作学习,彻底改变了病理学教育和培训。学生和学员可以远端查看、註释和讨论数位幻灯片,消除医学教育中的地理障碍。该细分市场的一个关键要求是存取综合数位幻灯片库和互动式学习工具,以促进远端教育和协作培训计划。
区域洞察
在先进技术的高采用率、完善的医疗基础设施以及该地区主要市场参与者的推动下,美洲的数位病理检测市场正在呈现显着成长。此外,FDA 监管部门的核准刺激了数位病理测试系统用于初级诊断的采用,从而促进了市场成长。在 EMEA(欧洲、中东和非洲)地区,随着欧洲各地对数位化病理诊断优势的认识不断增强,对数位病理测试解决方案的需求强劲。尤其是西欧,由于该地区强大的医疗保健系统以及医疗保健 IT 投资的增加,该地区的采用率尤其高。在持续的医疗保健现代化倡议的推动下,中东和非洲正在经历适度增长。由于慢性病的增加、医疗保健支出的增加以及对数位病理检测益处的认识不断增强,预计亚太地区将越来越多地采用数位病理检测解决方案。由于病理实验室数量的增加和研发活动的扩大,亚太地区的需求进一步增强。
FPNV定位矩阵
FPNV定位矩阵对于评估数位病理检测市场至关重要。我们检视与业务策略和产品满意度相关的关键指标,以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估,供应商被分为四个成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可以对数位病理测试市场中供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献,以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外,该分析还提供了对该行业竞争特征的宝贵见解,包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。详细程度的提高使供应商能够做出更明智的决策并制定有效的策略,以获得市场竞争优势。
1. 市场渗透率:提供有关主要企业所服务的市场的全面资讯。
2. 市场开拓:我们深入研究利润丰厚的新兴市场,并分析其在成熟细分市场的渗透率。
3. 市场多元化:提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。
4. 竞争评估和情报:对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况和製造能力进行全面评估。
5. 产品开发与创新:提供对未来技术、研发活动和突破性产品开发的见解。
1.数位病理检测市场规模及预测是多少?
2.在数位病理检测市场的预测期内,有哪些产品、细分市场、应用程式和领域需要考虑投资?
3.数位病理检测市场的技术趋势和法规结构是什么?
4.数位病理检测市场主要厂商的市场占有率为何?
5.进入数位病理检测市场合适的型态和策略手段是什么?
[197 Pages Report] The Digital Pathology Market size was estimated at USD 1.85 billion in 2023 and expected to reach USD 2.11 billion in 2024, at a CAGR 14.58% to reach USD 4.81 billion by 2030.
Digital pathology refers to acquiring, managing, sharing, and interpreting pathology information, including slides and data, in a digital environment. Digital pathology aims to enhance the efficiency and accuracy of pathological assessments, fostering better decision-making in diagnostics, research, and education within the medical field. It leverages advanced imaging technology, computer algorithms, and data analysis techniques to facilitate a more precise and comprehensive examination of tissue samples, enabling pathologists to detect diseases and conditions with improved clarity and detail. The digital pathology market is growing rapidly, owing to the growing need for high-quality diagnostics amid rising chronic disease prevalence, offering rapid, precise analysis and facilitating remote consultations to improve patient outcomes. However, the market grapples with notable hurdles, including the high costs associated with adopting digital systems and concerns over data security, alongside challenges in system integration. Despite these obstacles, burgeoning opportunities in artificial intelligence (AI) and machine learning for analysis automation, the expansion into emerging markets with developing healthcare infrastructure, and the potential for enhanced global research collaboration present significant growth prospects. This landscape illustrates a market poised for substantial evolution, promising to redefine pathological diagnostics and healthcare delivery.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 1.85 billion |
Estimated Year [2024] | USD 2.11 billion |
Forecast Year [2030] | USD 4.81 billion |
CAGR (%) | 14.58% |
Product: Growing shift towards cloud-based solutions for more flexible and cost-effective storage options
Digital pathology scanners are sophisticated devices used to convert traditional glass slides into digital slides by capturing high-resolution images. Laboratories may choose scanners based on their throughput needs, resolution requirements, and the types of specimens they commonly handle. High-throughput scanners are preferred in settings with large volumes of samples, such as in reference laboratories and academic centers, whereas smaller clinics might opt for compact, lower-throughput models. Software in digital pathology includes image analysis tools, workflow management systems, and telepathology solutions. These solutions enhance the value of digital slides by enabling detailed analysis, remote access, and efficient case management. Digital pathology generates vast amounts of data, necessitating robust storage solutions. Storage solutions are chosen based on the size of the operation, data security requirements, and accessibility needs. Larger institutions may need scalable cloud-based solutions, whereas smaller labs might opt for local storage systems with lower initial costs.
Application: Rising adoption of digital pathology to enhance the speed and accuracy of identifying potential therapeutic targets and understanding disease mechanisms
The application of digital pathology in disease diagnosis involves digitizing glass slides and using digital images for analysis, thus enabling pathologists to diagnose diseases, including cancer, more accurately and efficiently. This modality supports a diverse range of diagnostic procedures, including the analysis of cancerous cells, the grading of tumor samples, and the monitoring of disease progression. Digital pathology has a crucial role in the drug discovery process, particularly in the evaluation of drug efficacy and toxicology studies. By enabling the digital analysis of tissue samples, researchers can better understand the effects of drug candidates at the microscopic level. Digital pathology has revolutionized pathology education and training by offering access to a vast array of digital slides for teaching and collaborative learning. Students and trainees can view, annotate, and discuss digital slides remotely, breaking down geographical barriers in medical education. The primary requirement of this segment is the accessibility of comprehensive digital slide libraries and interactive learning tools that facilitate remote education and collaborative training programs.
Regional Insights
The digital pathology market in the Americas has shown significant growth, attributed to several factors, including the high adoption of advanced technologies, well-established healthcare infrastructure, and the presence of major market players in the region. Furthermore, regulatory approvals by the FDA have spurred the adoption of digital pathology systems for primary diagnostics, contributing to market growth. The EMEA region exhibits a robust demand for digital pathology solutions, driven by the growing awareness of the benefits of digitalization in pathology across Europe. Western Europe, in particular, demonstrates a high adoption rate owing to the region's strong healthcare systems and increasing investments in healthcare IT. The Middle East and Africa are witnessing gradual growth fueled by ongoing healthcare modernization initiatives. Asia-Pacific is anticipated to adopt digital pathology solutions more owing to the rising prevalence of chronic diseases, increasing healthcare expenditure, and growing awareness of digital pathology's benefits. The demand in APAC is further bolstered by the growing number of pathology laboratories and expanding research and development activities.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Digital Pathology Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Digital Pathology Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Digital Pathology Market, highlighting leading vendors and their innovative profiles. These include 3DHISTECH Ltd., Aiforia Technologies PLC, Charles River Laboratories, Corista LLC, DeepBio, Inc., Epredia, F. Hoffmann-La Roche Ltd., FUJIFILM Holdings Corporation, GE Healthcare, Hamamatsu Photonics K.K., Huron Digital Pathology, Indica Labs, Koninklijke Philips N.V., Laboratory Corporation of America Holdings, Leica Biosystems Nussloch GmbH, Mikroscan Technologies, Motic, Nikon Corporation, OptraSCAN, Inc., PathAI, Pathcore Inc., PathPresenter Corporation, PerkinElmer, Inc., Proscia, Inc., Sectra AB, Visiopharm A/S, and Xybion Digital Inc..
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Digital Pathology Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Digital Pathology Market?
3. What are the technology trends and regulatory frameworks in the Digital Pathology Market?
4. What is the market share of the leading vendors in the Digital Pathology Market?
5. Which modes and strategic moves are suitable for entering the Digital Pathology Market?